Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 52-Week Low – Time to Sell?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) hit a new 52-week low during trading on Friday. The company traded as low as $154.30 and last traded at $157.03, with a volume of 82,046 shares traded. The stock had previously closed at $156.66.

Analysts Set New Price Targets

ALNY has been the topic of a number of recent analyst reports. Raymond James Financial downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and lowered their price target for the stock from $420.00 to $315.00 in a report on Friday, October 30th. Truist Financial cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price objective for the company from $315.00 to $225.00 in a report on Monday. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. The Goldman Sachs Group decreased their price objective on shares of Alnylam Pharmaceuticals from $536.00 to $320.00 and set a “buy” rating for the company in a research report on Friday, October 30th. Finally, Chardan Capital lowered their target price on shares of Alnylam Pharmaceuticals from $425.00 to $375.00 and set a “buy” rating on the stock in a research note on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $305.86.

Alnylam Pharmaceuticals Stock Up 0.4%

The business’s 50 day moving average is $230.18 and its 200-day moving average is $282.09. The stock has a market cap of $21.06 billion, a price-to-earnings ratio of 8.15 and a beta of 0.42. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping the consensus estimate of $1.66 by $14.60. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The firm’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.90 EPS. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.85 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently modified their holdings of ALNY. Toth Financial Advisory Corp purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $25,000. Burkett Financial Services LLC acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $37,000. CoreCap Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 744.4% in the third quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 134 shares in the last quarter. Keating Financial Advisory Services Inc. acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $42,000. Finally, Root Financial Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $48,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.